Julie G. Allickson

Julie Allickson, Ph.D., is the Michael S. and Mary Sue Shannon director of Mayo Clinic’s Center for Regenerative Biotherapeutics and the Otto Bremer Trust director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics and Associate Professor of Regenerative Biotherapeutics. Dr. Allickson is leading the next phase of development of the Center for Regenerative Biotherapeutics as it delivers on innovations that Cure, Connect and Transform patient care in alignment with Mayo Clinic’s 2030 vision. She directs the enterprise-wide biomanufacturing strategy that aspires to introduce new regenerative therapeutics into the practice and establish Mayo Clinic as a category of one in regenerative medicine for rare and complex conditions. Dr. Allickson provides strategic leadership for all center activities and operations across Mayo Clinic. The Center for Regenerative Biotherapeutics has over 200 clinical trials and projects underway and has filed more than 150 regenerative patents. The center performs over 100,000 regenerative procedures annually. With more than 25 years of experience in clinical translation of cellular therapies and regenerative medicine products, Dr. Allickson has expertise in business management, regulatory affairs, strategic planning, project management and team building. She has served as an executive officer of a publicly traded company that builds services for cellular banking, including licensure of technology with international affiliates.